In order to further enhance their current longevity and steadily mitigate therapeutic burdens, CF must be treated beyond its symptoms by targeting the root cause of the disease, precluding thus the pathological cascade of events downstream of CFTR dysfunction. This evidence concerns the gene CFTR and cystic fibrosis.